Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines
Christina Kratzmeier, Mojtaba Taheri, Zhongcheng Mei, Isabelle Lim, May A. Khalil, Brandon Carter-Cooper, Rachel E. Fanaroff, Chin Siang Ong, Eric B. Schneider, Stephanie Chang, Erica Leyder, Dongge Li, Irina G. Luzina, Anirban Banerjee, Alexander Sasha Krupnick
Christina Kratzmeier, Mojtaba Taheri, Zhongcheng Mei, Isabelle Lim, May A. Khalil, Brandon Carter-Cooper, Rachel E. Fanaroff, Chin Siang Ong, Eric B. Schneider, Stephanie Chang, Erica Leyder, Dongge Li, Irina G. Luzina, Anirban Banerjee, Alexander Sasha Krupnick
View: Text | PDF
Research Article Cell biology Immunology Oncology

Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines

  • Text
  • PDF
Abstract

Because the lung is a mucosal barrier organ with a unique immunologic environment, mechanisms of immunoregulation in lung cancer may differ from those of other malignancies. Consistent with this notion, we found that CD8+ T cells played a paradoxical role in facilitating, rather than ameliorating, the growth of multiple lung adenocarcinoma models. These included spontaneous, carcinogen-induced, and transplantable tumor cell line models. Specifically, we found that CD8+ T cells promoted homing of CD4+Foxp3+ Tregs to the tumor bed by increasing the levels of CCR5 chemokines in the tumor microenvironment in an IFN-γ– and TNF-α–dependent manner. Contrary to their canonical role, these Th1 cytokines contributed to accelerated growth of murine lung adenocarcinomas, while suppressing the growth of other malignancies. Surprisingly, lung cancer cells themselves can serve as a dominant source of IFN-γ, and deletion of this cytokine from cancer cells using CRISPR/Cas9 decreases tumor growth. Importantly for translational applications, in patients with lung cancer, a high level of IFN-γ was also found at both the mRNA and protein levels. Our data outline what we deem a novel and previously undefined lung cancer–specific immunoregulatory pathway that may be harnessed to tailor immune-based therapy specifically for this malignancy.

Authors

Christina Kratzmeier, Mojtaba Taheri, Zhongcheng Mei, Isabelle Lim, May A. Khalil, Brandon Carter-Cooper, Rachel E. Fanaroff, Chin Siang Ong, Eric B. Schneider, Stephanie Chang, Erica Leyder, Dongge Li, Irina G. Luzina, Anirban Banerjee, Alexander Sasha Krupnick

×

Figure 4

Lung tumor microenvironment is enriched for IFN-γ.

Options: View larger image (or click on image) Download as PowerPoint
Lung tumor microenvironment is enriched for IFN-γ.
(A) MFI of chemokines...
(A) MFI of chemokines produced by CD8+ T cells and CD11b+ myeloid cells in the tumor bed of LLCova-bearing mice either with or without IFN-γ and TNF-α neutralization. (B) Cytoplex analysis of flank tumor beds indicating fold difference of cytokine levels for B6 and B6CD8–/– mice bearing LLCova or B16ova. All data were normalized for each cytokine based on the LLCova-bearing B6CD8–/– mouse group, which was set as 1. (C) Ifng mRNA levels from samples in TCGA for patients with melanoma, colon, pancreatic, or lung cancer that received no preoperative treatment. (D) Matched tissue samples (tumor and normal) from patients at the University of Maryland School of Medicine taken during resection prior to any preoperative treatment (colorectal cancer, n = 7 patients; pancreatic cancer, n = 6 patients; and lung cancer, n = 11 patients). (E) Tumor growth of B16ova and LLCova flank tumors in B6 mice with and without depletion of IFN-γ and TNF-α. Two-way ANOVA was used for (B), followed by unpaired, 2-tailed t test with Welch’s correction. Other plots were analyzed via Student’s unpaired, 2-tailed t test with Welch’s correction, with exception of Figure 4D, for which a paired, 2-tailed t test was used. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. NS = P > 0.05. Data represent the mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts